Malta - Tiếng Anh - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - pneumococcal polysaccharide, serotype, conjugated to, crm, b conjugated, to crm, f conjugated, n conjugated, v conjugated, a conjugated, c conjugated - solution for injection - pneumococcal polysaccharide serotype 1 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 2 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 3 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 4 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 5 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 6b conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 7f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 8 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 9n conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 9v conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 10a conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 11a conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 12f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 14 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 15b conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 17f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 18c conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 19f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 19a conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 19f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 20 conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 22f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 23f conjugated to crm197 50 µg/ml pneumococcal polysaccharide serotype 33f conjugated to crm197 50 µg/ml - vaccines

Malta - Tiếng Anh - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - mumps vaccine, rit, measles virus, schwarz strain, rubella virus, wistar ra - powder and solvent for solution for injection in pre-filled syringe - mumps vaccine rit 4385 measles virus - schwarz strain rubella virus - wistar ra27/3 strain - vaccines

Malta - Tiếng Anh - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - mumps vaccine, rit, measles virus, schwarz strain, rubella virus, wistar ra - powder and solvent for solution for injection - measles virus - schwarz strain rubella virus - wistar ra27/3 strain mumps vaccine rit 4385 - vaccines

Philippin - Tiếng Anh - FDA (Food And Drug Administration)

n/a; importer: 2 world traders inc.; distributor: 2 world traders inc. - pneumococcal polysaccharide conjugate vaccine, 13- valent (adsorbed) - suspension for injection (im) - each dose (0.5 ml) contains the capsular polysaccharide of the following streptococcus pneumoniae serotypes: pneumococcal polysaccharide serotype 6b pneumococcal polysaccharide serotype 18c pneumococcal polysaccharide serotype 4, 23f pneumococcal polysaccharide serotype 7f pneumococcal polysaccharide serotype 14, 19f pneumococcal polysaccharide serotype 1, 19a 6.0 με 3.25 μg 3.0 με 2.85 με - 2.75 με 2.6 με pneumococcal polysaccharide serotype 3, 5, 6a, 9v conjugated to tetanus toxoid carrier protein 2.5 με 41-150 με

Philippin - Tiếng Anh - FDA (Food And Drug Administration)

n/a; importer: 2 world traders inc.; distributor: 2 world traders inc. - pneumococcal polysaccharide conjugate vaccine, 13- valent (adsorbed) - suspension for injection (im) - each dose (0.5 ml) contains the capsular polysaccharide of the following streptococcus pneumoniae serotypes: pneumococcal polysaccharide serotype 6b pneumococcal polysaccharide serotype 18c pneumococcal polysaccharide serotype 4, 23f pneumococcal polysaccharide serotype 7f pneumococcal polysaccharide serotype 14, 19f pneumococcal polysaccharide serotype 1, 19a pneumococcal polysaccharide serotype 3, 5, 6a, 9v conjugated to tetanus toxoid carrier protein 6.0 με 3.25 μg 3.0 με 2.85 μg 2.75 μg 2.6 μg

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

wyeth pharmaceutical division of wyeth holdings llc - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 54ec0se5pz) (streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:54ec0se5pz), streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 2vf3v7175u) (streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:2vf3v7175u), streptococcus pneumoniae type - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen 2.2 ug in 0.5 ml - in children 6 weeks through 5 years of age (prior to the 6th birthday), prevnar 13® is indicated for: in children 6 years through 17 years of age (prior to the 18th birthday), prevnar 13 is indicated for: risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on prevnar 13 administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. a developmental toxicity study has been performed in female rabbits administered prevnar 13 prior to mating and during gestation. each dose was approximately 20 times the human dose. this study revealed no evidence of harm to the fetus due to prevnar 13 (see 8.1 data). data animal in a developmental toxicity study, female rabbits were administered prevnar 13 by intramuscular injection twice prior to mating (17 days an

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; phenol; sodium chloride - pneumovax 23 is indicated for immunisation of individuals in the following situations: all individuals over the age of 65 years; individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy; immunocompromised patients at increased risk of pneumococcal disease (eg patients with hiv infection before the development of aids, nephrotic syndrome, multiple myeloma, lymphoma, hodgkin's disease and organ transplantation); aboriginal and torres strait islander people over 50 years of age; immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg chronic cardiac, renal or pulmonary disease, diabetes mellitus, alcoholism and cirrhosis); patients with cerebrospinal fluid leaks. in australia, the national health and medical research council (nhmrc) currently recommends the vaccination of tobacco smokers with the 23-valent

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

Armenia - Tiếng Anh - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer manufacturing belgium n.v. - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f) - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 2 microgram; pneumococcal purified capsular polysaccharides, quantity: 4 microgram - injection, suspension - excipient ingredients: polysorbate 20; histidine; sodium chloride; aluminium; water for injections; diphtheria crm197 protein - vaxneuvance is indicated for active immunisation for the prevention of pneumococcal disease caused by streptococcus pneumoniae serotypes (1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f, 22f, 23f and 33f) in adults and children from 6 weeks of age. vaxneuvance may not prevent disease caused by s. pneumoniae serotypes that are not contained in the vaccine. the use of vaxneuvance should be guided by official recommendations.